Eliaz Therapeutics, Inc.

Go Beyond the Laboratory. Analyze the Science of Clinical Investment.

The RainMakers Collective Deals Access Pass grants you exclusive entry to our proprietary institutional-grade due diligence. This Investment Memo provides an unvarnished, comprehensive look at the Eliaz Therapeutics opportunity, stripping away the medical jargon to expose the financial burn rates, regulatory hurdles, and the realities of a pre-revenue clinical-stage play.

We have logged the hours dissecting the XGAL-3® model so you can make an informed decision in minutes. By purchasing this Deep-Dive Investment Memo, you will gain access to:

• The RainMakers Verdict: Access our professional final recommendation, analyzing if the potential for venture-scale returns outweighs the significant clinical and regulatory risks.

• The “IP Moat” Analysis: A deep dive into the intellectual property strategy protecting the XGAL-3® apheresis device with over 60 patents across 34 countries.

• FDA Breakthrough Valuation: An assessment of what the FDA Breakthrough Device Designation means for de-risking the venture and the potential for an expedited regulatory pathway.

• Financial Structure & Dilution: A transparent look at the $59.44M pre-money valuation, the “Going Concern” qualifications in the financial statements, and the reality of projected future dilution.

• Exit Scenario Modeling: Probability-weighted projections analyzing potential outcomes ranging from total loss to a strategic acquisition by a major medical technology giant.

• Team Track Record: A background check on founder Dr. Isaac Eliaz, his previous $30M+ exit, and the high-caliber advisory board supporting the mission.

• Strategic Partnership Analysis: A look at the collaboration with Terumo BCT and how this hardware partnership impacts the path to commercialization and market adoption.

   

Unlock the full picture. Purchase the Deals Access Pass for Eliaz Therapeutics today.